R. Kim, M. Emi, and K. Tanabe, Cancer immunoediting from immune surveillance to immune escape, Immunology, vol.1, issue.1, pp.1-14, 2007.
DOI : 10.1046/j.1440-1711.2002.01115.x

R. Marin, F. Ruiz-cabello, S. Pedrinaci, R. Mendez, and P. Jimenez, Analysis of HLA-E expression in human tumors, Immunogenetics, vol.54, issue.11, pp.767-775, 2003.

I. Algarra, A. Garcia-lora, T. Cabrera, F. Ruiz-cabello, and F. Garrido, The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape, Cancer Immunology, Immunotherapy, vol.53, issue.10, pp.904-910, 2004.
DOI : 10.1007/s00262-004-0517-9

M. Campoli and S. Ferrone, HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance, Oncogene, vol.14, issue.45, pp.5869-5885, 2008.
DOI : 10.1128/MCB.20.7.2592-2603.2000

N. Rouas-freiss, P. Moreau, S. Ferrone, and E. Carosella, HLA-G Proteins in Cancer: Do They Provide Tumor Cells with an Escape Mechanism?, Cancer Research, vol.65, issue.22, pp.10139-10144, 2005.
DOI : 10.1158/0008-5472.CAN-05-0097

B. Seliger, H. Abken, and S. Ferrone, HLA-G and MIC expression in tumors and their role in anti-tumor immunity, Trends in Immunology, vol.24, issue.2, pp.82-87, 2003.
DOI : 10.1016/S1471-4906(02)00039-X

N. Bangia and S. Ferrone, Antigen Presentation Machinery (APM) Modulation and Soluble HLA Molecules in the Tumor Microenvironment: Do They Provide Tumor Cells with Escape Mechanisms from Recognition by Cytotoxic T Lymphocytes?, Immunological Investigations, vol.90, issue.3-4, pp.3-4, 2006.
DOI : 10.1038/226366a0

M. Campoli and S. Ferrone, Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands, Tissue Antigens, vol.23, issue.4, pp.321-334, 2008.
DOI : 10.1111/j.1399-0039.2008.01106.x

R. Bahri, F. Hirsch, A. Josse, N. Rouas-freiss, and N. Bidere, Soluble HLA-G Inhibits Cell Cycle Progression in Human Alloreactive T Lymphocytes, The Journal of Immunology, vol.176, issue.3, pp.1331-1339, 2006.
DOI : 10.4049/jimmunol.176.3.1331

P. Contini, M. Ghio, A. Poggi, G. Filaci, and F. Indiveri, Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T???cell activity through CD8 ligation, European Journal of Immunology, vol.33, issue.1, pp.125-134, 2003.
DOI : 10.1002/immu.200390015

W. Tabayoyong and N. Zavazava, Soluble HLA revisited, Leukemia Research, vol.31, issue.2, pp.121-125, 2007.
DOI : 10.1016/j.leukres.2006.06.008
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876709

L. Derre, M. Corvaisier, B. Charreau, A. Moreau, and E. Godefroy, Expression and Release of HLA-E by Melanoma Cells and Melanocytes: Potential Impact on the Response of Cytotoxic Effector Cells, The Journal of Immunology, vol.177, issue.5, pp.3100-3107, 2006.
DOI : 10.4049/jimmunol.177.5.3100

L. Derre, M. Corvaisier, M. Pandolfino, E. Diez, and F. Jotereau, Expression of CD94/NKG2-A on Human T Lymphocytes Is Induced by IL-12: Implications for Adoptive Immunotherapy, The Journal of Immunology, vol.168, issue.10, pp.4864-4870, 2002.
DOI : 10.4049/jimmunol.168.10.4864

L. Drean, E. Vely, F. Olcese, L. Cambiaggi, A. Guia et al., Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases, European Journal of Immunology, vol.24, issue.1, pp.264-276, 1998.
DOI : 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O

K. Malmberg, V. Levitsky, H. Norell, C. De-matos, and M. Carlsten, IFN-?? protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism, Journal of Clinical Investigation, vol.110, issue.10, pp.1515-1523, 2002.
DOI : 10.1172/JCI0215564

D. Speiser, M. Pittet, D. Valmori, R. Dunbar, and D. Rimoldi, In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma???Specific Cytolytic T Lymphocytes, The Journal of Experimental Medicine, vol.155, issue.6, pp.775-782, 1999.
DOI : 10.1002/(SICI)1521-4141(199805)28:05<1611::AID-IMMU1611>3.0.CO;2-6

V. Rebmann, H. Nuckel, U. Duhrsen, and H. Grosse-wilde, HLA-G in B-chronic lymphocytic leukaemia: Clinical relevance and functional implications, Seminars in Cancer Biology, vol.17, issue.6, pp.430-435, 2007.
DOI : 10.1016/j.semcancer.2007.06.011

V. Rebmann, J. Regel, D. Stolke, and H. Grosse-wilde, Secretion of sHLA-G molecules in malignancies, Seminars in Cancer Biology, vol.13, issue.5, pp.371-377, 2003.
DOI : 10.1016/S1044-579X(03)00028-2

V. Rebmann, S. Wagner, and H. Grosse-wilde, HLA-G expression in malignant melanoma, Seminars in Cancer Biology, vol.17, issue.6, pp.422-429, 2007.
DOI : 10.1016/j.semcancer.2007.06.010

P. Schutt, B. Schutt, M. Switala, S. Bauer, and G. Stamatis, Prognostic relevance of soluble human leukocyte antigen???G and total human leukocyte antigen class I molecules in lung cancer patients, Human Immunology, vol.71, issue.5, pp.489-495, 2010.
DOI : 10.1016/j.humimm.2010.02.015

Y. Sebti, L. Friec, G. Pangault, C. Gros, F. Drenou et al., Soluble HLA-G molecules are increased in lymphoproliferative disorders, Human Immunology, vol.64, issue.11, pp.1093-1101, 2003.
DOI : 10.1016/j.humimm.2003.08.345

C. Zhu, C. Wang, X. Zhang, J. Zhang, and W. Li, Serum sHLA-G levels: A useful indicator in distinguishing colorectal cancer from benign colorectal diseases, International Journal of Cancer, vol.66, issue.3, pp.617-622, 2011.
DOI : 10.1002/ijc.25372

G. Singer, V. Rebmann, Y. Chen, H. Liu, and S. Ali, HLA-G is a potential tumor marker in malignant ascites, Clin Cancer Res, vol.9, issue.12, pp.4460-4464, 2003.

N. Arreygue-garcia, A. Daneri-navarro, A. Del-toro-arreola, A. Cid-arregui, and O. Gonzalez-ramella, Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions, BMC Cancer, vol.33, issue.1, p.16, 2008.
DOI : 10.1002/immu.200390015

S. Holdenrieder, P. Stieber, A. Peterfi, D. Nagel, and A. Steinle, Soluble MICA in malignant diseases, International Journal of Cancer, vol.53, issue.3, pp.684-687, 2006.
DOI : 10.1002/ijc.21382

S. Holdenrieder, P. Stieber, A. Peterfi, D. Nagel, and A. Steinle, Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA, Cancer Immunology, Immunotherapy, vol.285, issue.12, pp.1584-1589, 2006.
DOI : 10.1007/s00262-006-0167-1

E. Levy, M. Bianchini, V. Euw, E. Barrio, M. Bravo et al., Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer, International Journal of Oncology, vol.32, issue.3, pp.633-641, 2008.
DOI : 10.3892/ijo.32.3.633

A. Sprague and R. Khalil, Inflammatory cytokines in vascular dysfunction and vascular disease, Biochemical Pharmacology, vol.78, issue.6, pp.539-552, 2009.
DOI : 10.1016/j.bcp.2009.04.029

S. Coupel, A. Moreau, M. Hamidou, V. Horejsi, and J. Soulillou, Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation, Blood, vol.109, issue.7, pp.2806-2814, 2007.
DOI : 10.1182/blood-2006-06-030213

O. Kholmanskikh, N. Van-baren, F. Brasseur, S. Ottaviani, and J. Vanacker, Interleukins 1?? and 1?? secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens, International Journal of Cancer, vol.125, issue.7, pp.1625-1636, 2010.
DOI : 10.1002/ijc.25182

S. Yeruva, G. Ramadori, and D. Raddatz, NF-??B-dependent synergistic regulation of CXCL10 gene expression by IL-1?? and IFN-?? in human intestinal epithelial cell lines, International Journal of Colorectal Disease, vol.19, issue.3, pp.305-317, 2008.
DOI : 10.1007/s00384-007-0396-6

S. Bracarda, J. Bellmunt, B. Melichar, S. Negrier, and E. Bajetta, Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-??2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial, BJU International, vol.76, issue.2, pp.214-219, 2011.
DOI : 10.1111/j.1464-410X.2010.09707.x

S. Ugurel, V. Rebmann, S. Ferrone, W. Tilgen, and H. Grosse-wilde, Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-? immunotherapy, Cancer, vol.42, issue.2, pp.369-376, 2001.
DOI : 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U

S. Michelin, C. Gallegos, D. Dubner, B. Favier, and E. Carosella, Ionizing radiation modulates the surface expression of human leukocyte antigen-G in a human melanoma cell line, Human Immunology, vol.70, issue.12, pp.1010-1015, 2009.
DOI : 10.1016/j.humimm.2009.07.030

D. Bainbridge, S. Ellis, and I. Sargent, HLA-G suppresses proliferation of CD4+ T-lymphocytes, Journal of Reproductive Immunology, vol.48, issue.1, pp.17-26, 2000.
DOI : 10.1016/S0165-0378(00)00070-X

S. Fournel, M. Aguerre-girr, X. Huc, F. Lenfant, and A. Alam, Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD8, The Journal of Immunology, vol.164, issue.12, pp.6100-6104, 2000.
DOI : 10.4049/jimmunol.164.12.6100

F. Gros, F. Cabillic, O. Toutirais, A. Maux, and Y. Sebti, Soluble HLA-G molecules impair natural killer/dendritic cell crosstalkvia inhibition of dendritic cells, European Journal of Immunology, vol.43, issue.3, pp.742-749, 2008.
DOI : 10.1002/eji.200736918

N. Rouas-freiss, R. Goncalves, C. Menier, J. Dausset, and E. Carosella, Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis, Proceedings of the National Academy of Sciences, vol.94, issue.21, pp.94-11520, 1997.
DOI : 10.1073/pnas.94.21.11520

V. Groh, J. Wu, C. Yee, and T. Spies, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.17, issue.6908, pp.734-738, 2002.
DOI : 10.1126/science.285.5428.730

M. Zhong, X. Weng, Z. Liang, S. Lu, and J. Li, Dimerization of Soluble HLA-G by IgG-Fc Fragment Augments ILT2-Mediated Inhibition of T-Cell Alloresponse, Transplantation, vol.87, issue.1, pp.8-15, 2009.
DOI : 10.1097/TP.0b013e31818b6141

A. Perier, G. Fregni, S. Wittnebel, S. Gad, and M. Allard, Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene;Epub ahead of print, 2011.